卵巢癌是大脑转移（BM）的少见起源，发生率仅为1％-3％。因此，文献匮乏，对卵巢BM没有治疗共识指南可用。作者对卵巢BM进行了系统综述，并与他们的病例系列进行了合并的队列生存分析。 按照PRISMA指南，进行了与PubMed，Scopus和Web of Science一致的系统综述，并进行了机构的回顾性病历审查。系统综述的纳入标准包括确诊BM和原发性卵巢癌患者，报告围手术期并发症和结果，分化组织学，并明确报告个体患者数据。排除了评论、评论、技术说明和没有英语翻译的文章。作者1和2使用Newcastle-Ottawa质量评估量表独立评估了每篇文章的质量。作者对多个生存预后因素进行了单变量和多变量分析。针对单变量分析中的重要预后因素生成了Kaplan-Meier曲线。 纳入了34项研究中的48名有个体数据的患者以及作者机构的8名患者。所有患者（n = 56）均接受了大脑转移的切除手术；手术后83.9％的患者接受了辅助放疗，41.1％的患者接受了辅助化疗。中位无进展生存期为12个月（范围2-43个月）。中位总生存期为9个月（范围1-49个月）。在单变量分析中，单个大脑转移和无颅外转移对生存有益，而以透明细胞癌为主要组织学的患者则对总生存期较差。多变量分析显示年龄> 50岁（p = 0.002）和> 1个大脑转移（p < 0.001）是不良预后的危险因素。保护性因素包括以下多模式辅助治疗与手术联合使用：放疗（p = 0.002），化疗和放疗（p = 0.005），以及立体定向放射外科术（p = 0.002）。 尽管已发表的个体患者数据的稀缺性阻碍了确定最佳管理的确定，但作者的分析突出了多模式治疗，单个颅内损害和年龄<50岁与卵巢BM患者生存增加相关。

Ovarian cancer is a rare origin of brain metastasis (BM), with an incidence of only 1%-3%. Consequently, the literature is sparse, and no treatment consensus guideline is available for ovarian BM. The authors conducted a systematic review of ovarian BM and performed a combined pooled cohort survival analysis with their case series.A systematic review of PubMed, Scopus, and Web of Science consistent with PRISMA guidelines along with an institutional retrospective chart review was conducted. Inclusion criteria for the systematic review included patients with confirmed BM and primary ovarian cancer, reported perioperative complications and outcomes, differentiated histology, and explicitly reported individual patient data. Reviews, commentaries, technical notes, and articles without English-language translations were excluded. The Newcastle-Ottawa Quality Assessment Scale was used independently by the first and second authors to assess the quality of each article. The authors performed univariate and multivariate analyses of several survival prognostic factors. Kaplan-Meier curves were generated for significant prognostic factors in the univariate analysis.A total of 48 patients with individual data across 34 studies and 8 patients from the authors' institution were included. All patients (n = 56) underwent resection for BM; 83.9% received adjuvant radiotherapy following surgery and 41.1% of patients received adjuvant chemotherapy. The median progression-free survival was 12 months (range 2-43 months). The median overall survival was 9 months (range 1-49 months). On univariate analysis, a single BM and no extracranial metastasis conferred a survival benefit, while clear cell carcinoma as the primary histology corresponded to worsened OS. Multivariable analysis showed that age > 50 years (p = 0.002) and > 1 BM (p < 0.001) were risk factors for poor prognosis. Protective factors included the addition of the following multimodal adjuvant therapy with surgery: radiotherapy (p = 0.002), chemotherapy and radiotherapy (p = 0.005), and stereotactic radiosurgery (p = 0.002).Although the scarcity of published individual patient data hinders the determination of optimal management, the authors' analysis highlights that multimodal therapies, a single cranial lesion, and age < 50 years are associated with increased survival for patients with ovarian BMs.